FundingPayments

Imugene: Receives $4.8M tax rebate on cancer research

  • Clinical-stage immuno-oncology company Imugene (IMU) has received a hefty tax rebate for its research and development (R&D) spending
  • The company has banked a little over $4.82 M as part of the Australian government’s R&D tax incentive program
  • The scheme also provides eligible Australian companies with an offset or refund of up to 43.5 percent of annual research spending
  • Then the company has a number of therapies in the pipeline to treat tumours, harnessing the body’s immune system to fight cancer’s growth and spread
  • With an extra $4.82M on hand, the company will well funded and resourced to continue the development of its potentially life-saving immunotherapies
  • Imugene closed Thursday’s session grey at 11.5. cents
Previous article
Identitii: Launches secure payments project with HomeSend
Next article
Scotiabank: Introduces real-time payments through Interac e-Transfer for Business
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

Venmo Strengthens Global Transfers by Allowing Payments to PayPal Accounts

Venmo users can now send money internationally to PayPal accounts.Highlights: Venmo now allows users to send money to...
FinTech

Talos and Nasdaq Strengthen On-Chain and Off-Chain Collateral Workflow

New partnership enhances digital asset handling and collateral management.Highlights: Talos and Nasdaq collaborate to streamline collateral workflows.Partnership aims...
FinTech

FCA Restricts Use of Sensitive Data in AI Trial with Palantir

Regulatory concerns arise over data handling protocols in AI trials.Highlights: FCA criticized for using sensitive data in AI...
FinTech

Bank of Ireland Strengthens AI Readiness for Staff Training

New initiatives prepare employees for an AI-driven banking landscape.Highlights: Bank of Ireland launches AI training initiatives for staff.Employees...